NCT05641259View on ClinicalTrials.gov

A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

PHASE1RecruitingINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

February 14, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia
Interventions
DRUG

LP-108

Oral administration for 21 or 28 days on a 28-day cycle

DRUG

Azacitidine

Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.

Trial Locations (3)

Unknown

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

RECRUITING

First Affiliated Hospital of Soochow University, Suzhou

RECRUITING

Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Guangzhou Lupeng Pharmaceutical Company LTD.

INDUSTRY